Peer-influenced content. Sources you trust. No registration required. This is HCN.
Practical Neurology
This study enrolled individuals with AD who had been on a stable dose of donezepil forat least 90 days. They were then treated for 12 weeks with the addition of themodulator of cholinergic neurotransmission AD101, or placebo. Those receiving AD101had mean improvement of approximately 2 points on the Alzheimer DiseaseAssessment Scale-Cognitive (ADAS-Cog) Subscale. Individuals who had continued donezepil plusplacebo showed declines on ADAS-Cog.
Neurology August 16th 2022
The update, which was presented during a panel discussion at the Alzheimer Association International Conference 2022 (AAIC2022) in San Diego, CA, is based on evidence from real-world use of aducanumab and is intended to improve risk mitigation, safety monitoring, patient selection, and shared decision-making.
Neurology August 8th 2022
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS